Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022 - Press Release

In Phase 1 studies, cudetaxestat displayed low potential for drug-drug interactions when dosed with approved therapies for idiopathic pulmonary fibros

Related Keywords

Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Bassem Elmankabadi ,International Congress ,Blade Therapeutics Inc ,European Respiratory Society ,